Why you might not be losing weight on Mounjaro — and what to do next

The dose you're on might simply not be your working dose yet

This is the question worth asking first. Mounjaro begins at 2.5mg, a strength that exists to let your body adjust to the medicine rather than to produce weight loss. Many people feel little appetite suppression at this level, which is expected. The prescriber-led titration schedule moves you up through 5mg, 7.5mg and beyond, typically in four-week steps, and for most people the noticeable reduction in hunger arrives somewhere in that climb.

If you've been on Mounjaro for six to eight weeks and are still on 2.5mg or 5mg, it's genuinely too early to conclude the medicine isn't working. The SURMOUNT-1 trial, published in the New England Journal of Medicine, tracked participants over 72 weeks; the steepest weight loss tended to occur across the middle months as doses increased, not in the first few weeks. Patience at the lower doses isn't passive, it's the plan working as designed.

If you're already at a higher dose and still not seeing movement, that's a different conversation, and one for your prescriber. A clinical review can look at whether your current dose is the right one, whether something else is going on, and what the next step should be. Our clinical team reviews exactly these questions as part of every repeat assessment.

What you're eating and drinking still matters, a lot

Mounjaro reduces appetite significantly for most people, but it doesn't override calories entirely. The medicine works alongside a reduced-calorie diet and increased activity; the licence says so explicitly, and the trial results were achieved under those conditions. If the appetite suppression is making you eat less but the foods you are eating are calorie-dense or liquid-based (smoothies, alcohol, juice, sauces), the deficit may be smaller than it looks.

Protein intake deserves particular attention. When weight loss happens fast, muscle can be lost alongside fat. Keeping protein reasonably high (and including some resistance activity) helps preserve lean mass, which in turn keeps metabolic rate from dropping sharply. This isn't a dosing instruction; it's the kind of practical conversation worth having with your prescriber or a dietitian who understands GLP-1 treatment.

Sleep and stress are less obvious contributors. Poor sleep is reliably associated with higher cortisol, which can drive fat retention and reduce the effectiveness of a calorie deficit. If you're managing a stressful period (a difficult few weeks at work, irregular nights) the scale may not move even when everything else is right. Worth factoring in before concluding the medicine has stopped working.

For broader context on how eating patterns interact with weight management medicines, the NHS medicines page for tirzepatide sets out the lifestyle components the treatment is designed to sit alongside.

Plateaus are real, documented and temporary, but they do need monitoring

A plateau is a period of two to four weeks where the scale doesn't move despite continued treatment. These happen to almost everyone on a long weight-loss journey, whether they're on medication or not. The body adjusts its energy expenditure as weight drops, which means the same deficit produces a smaller loss over time. This is physiology, not failure.

On Mounjaro, a plateau partway through treatment is common and was observed in clinical trial data. It does not mean the medicine has stopped being effective, it may mean the dose needs reviewing, or that the lifestyle elements need recalibrating. What it rarely means is that the medicine simply doesn't work for you; the evidence base behind tirzepatide is substantial, and genuine non-responders are a small minority.

If a plateau has lasted more than four to six weeks without explanation, that's the right time to speak to your prescriber. A dose adjustment, a look at recent eating patterns, or a check for any underlying factors (thyroid function, for instance) can all be part of that review. Our frequently asked questions cover some of the common reasons progress stalls and what a clinical review looks at.

One thing worth noting: if your plateau has coincided with a disrupted routine (a holiday, a run of late nights around a busy period at work, or even just a month where your usual pattern shifted) that context matters. Routine disruption is one of the most common reasons weight loss pauses mid-treatment, and re-establishing structure often restarts progress without any change to the medicine itself.

When to ask your prescriber to review your treatment

Not all slow progress is the same. There's a difference between a short-term plateau on a lower dose, a persistent stall at a therapeutic dose with good lifestyle habits, and a situation where side effects are making it hard to eat well or maintain activity. Your prescriber needs to know about all of these, and the information looks different in each case. If you find yourself thinking you're on Mounjaro and not losing weight, it helps to understand which of these situations applies to you before your next clinical review.

NICE guidance on tirzepatide (TA1026) notes that continuing treatment should be reviewed if less than 5% of body weight has been lost after six months at the highest tolerated dose. That's a clinical threshold, not a target to worry about day to day; it exists to make sure people aren't continuing a treatment that genuinely isn't working for them. Our guidance on what to do if you are not losing any weight on Mounjaro walks through how that threshold sits within the broader picture of your treatment. Similarly, if you feel on Mounjaro but not losing weight despite several weeks at a steady dose, a structured review of your progress is the appropriate next step. For those who want a fuller breakdown of the factors involved, our page covering not losing weight on Mounjaro goes into more detail on what a prescriber will typically look at. And if you feel you are on Mounjaro and not losing weight after a sustained period at a therapeutic dose, raising this directly in your repeat assessment is the right course of action.

If you're on Mounjaro through nume, clinical review is built into every repeat. A real prescriber reads your update before each supply is issued. If something isn't working, that's the place to say so, not in a helpline queue, but in the same clinical assessment process that started your treatment. You can also explore what the full treatment journey looks like on our Mounjaro information page, or look at the broader range of options on the weight loss treatments overview.

If you're not yet started and weighing up whether this is right for you, the right next step is a clinical conversation rather than more reading. Start your free consultation and let a prescriber look at your specific situation.